Literature DB >> 9382615

Early HIV-1 infection of the central nervous system.

S F An1, F Scaravilli.   

Abstract

There is a consensus of opinion that central nervous system (CNS) involvement takes place in a large proportion of patients with the acquired immune deficiency syndrome (AIDS). However, uncertainty still remains about how often and how early the CNS is infected during the early asymptomatic stage as some researchers still believe that low copy of human immunodeficiency virus type 1 (HIV-1) identified in the brains using polymerase chain reaction (PCR) represents HIV harboured in the infected cells trapped in cerebral blood vessels. In this review, the neurological abnormalities in HIV-1 positive pre-AIDS individuals are discussed from three points of view: neuropsychiatric and neurophysiological, involvement of cerebrospinal fluid (CSF) and brain pathology. In particular, our investigations of the brains of asymptomatic individuals have demonstrated that HIV-1 DNA was present in about half (17/36) of brains studied (copy numbers of HIV-1 DNA were detected and the possibility of contamination from the blood was calculated and excluded). Astro- (34/36) and micro- (31/36) gliosis and meningitis (11/36) were found. Immune activation, revealed by elevated expression of major histocompatibility complex (MHC) class II antigens, was previously demonstrated in the brains of patients with AIDS and was also present before the development of AIDS. Furthermore, demonstration of highly expressed cytokines (tumor necrosis factor (TNF)-alpha, interleukin (IL)-1, 4, 6) possibly explains the neuropathological changes and neuronal damage (confirmed by the demonstration of apoptotic neurons by in situ end labelling) seen in these brains. We conclude that HIV-1 is present in the brains of HIV-1 infected individuals at early stages of the infection and that HIV-1 induces brain damage in a direct as well as indirect way. This is a worrying conclusion which makes it mandatory to reconsider the time at which treatment must be applied in HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9382615

Source DB:  PubMed          Journal:  Arch Anat Cytol Pathol        ISSN: 0395-501X


  10 in total

1.  In vitro activation of feline immunodeficiency virus in ramified microglial cells from asymptomatically infected cats.

Authors:  A Hein; J P Martin; R Dörries
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

Review 2.  Towards nanomedicines for neuroAIDS.

Authors:  Vidya Sagar; Sudheesh Pilakka-Kanthikeel; Ravi Pottathil; Shailendra K Saxena; Madhavan Nair
Journal:  Rev Med Virol       Date:  2014-01-07       Impact factor: 6.989

3.  Phenylbutyric acid suppresses protein accumulation-mediated ER stress in retrovirus-infected astrocytes and delays onset of paralysis in infected mice.

Authors:  Xianghong Kuang; Wenhui Hu; Mingshan Yan; Paul K Y Wong
Journal:  Neurochem Int       Date:  2010-09-08       Impact factor: 3.921

4.  Links between progressive HIV-1 infection of humanized mice and viral neuropathogenesis.

Authors:  Santhi Gorantla; Edward Makarov; Jennifer Finke-Dwyer; Antonio Castanedo; Adelina Holguin; Catherine L Gebhart; Howard E Gendelman; Larisa Poluektova
Journal:  Am J Pathol       Date:  2010-11-18       Impact factor: 4.307

5.  Variation in the biological properties of HIV-1 R5 envelopes: implications of envelope structure, transmission and pathogenesis.

Authors:  Maria José Duenas-Decamp; Paul J Peters; Alexander Repik; Thomas Musich; Maria Paz Gonzalez-Perez; Catherine Caron; Richard Brown; Jonathan Ball; Paul R Clapham
Journal:  Future Virol       Date:  2010-07       Impact factor: 1.831

6.  Neuroprotective activities of CEP-1347 in models of neuroAIDS.

Authors:  Dawn Eggert; Prasanta K Dash; Santhi Gorantla; Huanyu Dou; Giovanni Schifitto; Sanjay B Maggirwar; Stephen Dewhurst; Larisa Poluektova; Harris A Gelbard; Howard E Gendelman
Journal:  J Immunol       Date:  2009-12-04       Impact factor: 5.422

7.  White matter abnormalities revealed by diffusion tensor imaging in non-demented and demented HIV+ patients.

Authors:  Yasheng Chen; Hongyu An; Hongtu Zhu; Taylor Stone; J Keith Smith; Colin Hall; Elizabeth Bullitt; Dinggang Shen; Weili Lin
Journal:  Neuroimage       Date:  2009-04-17       Impact factor: 6.556

Review 8.  HIV-associated neurocognitive disorders: perspective on management strategies.

Authors:  Linda Nabha; Lan Duong; Joseph Timpone
Journal:  Drugs       Date:  2013-06       Impact factor: 9.546

9.  Dynamics of viral and proviral loads of feline immunodeficiency virus within the feline central nervous system during the acute phase following intravenous infection.

Authors:  G Ryan; D Klein; E Knapp; M J Hosie; T Grimes; M J E M F Mabruk; O Jarrett; J J Callanan
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

Review 10.  Neuroimmune Mechanisms as Novel Treatment Targets for Substance Use Disorders and Associated Comorbidities.

Authors:  Mark D Namba; Jonna M Leyrer-Jackson; Erin K Nagy; M Foster Olive; Janet L Neisewander
Journal:  Front Neurosci       Date:  2021-04-15       Impact factor: 4.677

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.